Hypertension, Vol 3, 205-210, Copyright © 1981 by American Heart Association
SR Maitra, AG Scicli, S Miyazaki and OA Carretero
The chronic antihypertensive effect of converting enzyme inhibtor (CEI) may
be due to a decrease in aldosterone secretion secondary to blockade of
angiotensin II formation. To study this hypothesis, changes in blood
pressure (BP), in response to chronic administration of the CEI, captopril,
were measured in spontaneously hypertensive (SHR) and in chronic
two-kidney, one clip hypertensive (2K-1C) rats. To avoid a decrease in
mineralocorticoid activity, half of the rats in these two models of
hypertension were adrenalectomized and maintained with daily
administrations of deoxycorticosterone acetate and hydrocortisone (steroid
replacement) while the other half had the adrenal gland left in situ and no
exogenous steroids administered. The doses of steroids used were devoid of
hypertensive effect in Wistar Kyoto (WKY), SHR, 2K- 1C, and sham-clipped
rats. Chronic administration of the CEI decreased the BP to normotensive
levels in the SHR with intact adrenals and no steroid replacement. However,
the antihypertensive effect of the CEI was almost completely blocked in
those SHR with steroid replacement. In contrast, the antihypertensive
effect of the CEI in 2K-1C was similar in the rats with steroid replacement
and in the rats with intact adrenals (no steroid replacement). These
results suggest that the chronic antihypertensive effect of CEI in SHR is
due partially to a decrease in aldosterone activity secondary to the
blockade of angiotensin II formation, whereas in 2K-1C it is due to
mechanisms other than lower mineralocorticoid activity.
ARTICLES
Role of mineralocorticoid in the chronic antihypertensive effect of converting enzyme inhibitor
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1981 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |